Assessing the Next Wave of Oncology First Launches

Posted by Ben Hohn on Jul 2, 2019 11:39:30 AM

Judith Kulich, Jon Roffman, Cody Powers and Renuka Agarwal co-wrote this blog post with Ben Hohn.

The 2019 BIO International Conference, held June 3-6 in Philadelphia, attracted more than 16,000 attendees from more than 70 countries, with representation from biotechnology and pharmaceutical companies, academic institutions, regulators, investors and other organizations. The conference provided a platform for discovery and discussion, resulting in more than 41,000 partnering meetings.


>
Read More

Five Key Insights From Oncology First Launches

Posted by Ben Hohn on May 31, 2019 9:27:29 AM

Judith Kulich, Jon Roffman, Cody Powers and Renuka Agarwal co-wrote this blog post with Ben Hohn.

Oncology continues to be the leading therapeutic area for first launches by emerging biopharma companies in the United States. Recent ZS analysis identified 125 U.S. biopharma companies with first launches from 2011 to 2018, and 51 of those were for novel drugs. Of these 51,14 were in oncology—the largest number of any therapeutic area.


>
Read More

Five Observations From Successful Oncology ‘First Launches’

Posted by Ben Hohn on Aug 14, 2017 10:29:32 AM

Nicholas Martinez and Cody Powers co-wrote this blog post with Ben Hohn.

The stakes are high when preparing to launch a new drug, but for a biopharmaceutical company staring down its first-ever oncology launch, the stakes are even higher. Drug launches in the oncology space have grown increasingly competitive and occur more frequently than in any other therapeutic category. And of the 202 novel drugs approved by the FDA from 2011 to 2016, five were oncology drugs launched in the U.S. by publicly traded newcomers—so-called “first launches.”  


>
Read More